MSO Uplisting to Nasdaq and NYSE: Requirements, Timeline, and Market Impact

Executive Summary

Multi-state cannabis operators are pursuing uplisting from over-the-counter markets to major U.S. stock exchanges following federal rescheduling and regulatory changes that began in 2024. The process requires operators to obtain DEA registration, achieve compliance with exchange listing standards including minimum share price thresholds, and navigate complex federal securities law. Ascend Wellness Holdings became the latest MSO to announce uplisting preparations in July 2026, joining Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings in pursuing listings on the Nasdaq or New York Stock Exchange. The uplisting wave represents a fundamental shift in cannabis capital markets, potentially unlocking institutional investment from pension funds, index funds, and mutual funds that face regulatory restrictions on OTC securities. Successful uplisting could inject billions of dollars in new capital into the sector while reducing cost of capital for operators by 300-500 basis points. The transition also carries risks including increased disclosure requirements, quarterly earnings pressure, and potential share price volatility as institutional algorithms enter the market.

Why MSO Uplisting Matters

Uplisting to major exchanges affects $28 billion in U.S. cannabis market capitalization and determines whether institutional investors managing $40 trillion in assets can participate in the sector. The over-the-counter markets where cannabis operators currently trade—primarily the OTCQX and Canadian Stock Exchange—impose significant capital constraints on the industry. Institutional investors including pension funds, many mutual funds, and index funds face internal policies or fiduciary restrictions that prohibit or limit investment in OTC securities due to liquidity concerns and regulatory classification. According to data from Viridian Capital Advisors, approximately 87% of U.S. institutional capital remains unavailable to cannabis operators trading on OTC markets as of mid-2026. For operators, OTC trading translates directly to higher cost of capital. Multi-state operators reported weighted average cost of capital between 12% and 18% in 2025, compared to 6-8% for similarly-sized retail and consumer packaged goods companies trading on major exchanges. This differential forces operators to rely on expensive debt financing, sale-leaseback transactions, and dilutive equity raises that pressure existing shareholders. Patients and consumers face indirect impacts through reduced competition and slower market maturation. High capital costs limit MSO expansion into new markets, slow facility upgrades, and reduce investment in product innovation and quality control systems. State programs in emerging markets like Ohio and Pennsylvania have experienced supply constraints partly attributable to limited operator access to growth capital. The uplisting process also affects approximately 425,000 direct cannabis industry employees and an estimated 1.1 million indirect jobs in ancillary sectors. Publicly-traded companies on major exchanges typically offer more robust employee stock ownership programs and equity compensation, creating wealth-building opportunities for workers that OTC-traded companies struggle to provide due to liquidity limitations.

Background and History: The Path to Exchange Eligibility

Cannabis operators have been locked out of major U.S. exchanges since the Controlled Substances Act classified marijuana as Schedule I in 1970, creating a five-decade barrier that began to crack in 2024.

The Controlled Substances Act and Exchange Prohibition (1970-2024)

The Controlled Substances Act of 1970 placed cannabis in Schedule I alongside heroin and LSD, defining it as having no accepted medical use and high potential for abuse under 21 U.S.C. § 812. This classification created immediate consequences for capital markets. The Nasdaq Stock Market and New York Stock Exchange, operating under Securities and Exchange Commission oversight, adopted policies prohibiting listing of companies engaged in activities illegal under federal law. These policies remained in force for 54 years. Canadian operators found a workaround beginning in 2018 when Canada legalized adult-use cannabis nationally. Companies including Canopy Growth, Tilray, and Cronos Group listed on the NYSE and Nasdaq because their plant-touching operations occurred entirely in Canada, where the activity was federally legal. U.S. multi-state operators remained excluded because their cultivation, processing, and retail operations violated the Controlled Substances Act regardless of state-law compliance.

State Legalization and the OTC Market Emergence (2012-2020)

Colorado and Washington voters approved adult-use legalization in November 2012, with sales beginning in 2014. This created the first legal framework for vertically-integrated cannabis businesses operating at commercial scale. Early operators including Medicine Man Technologies, Dixie Brands, and Green Thumb Industries needed access to public capital markets but faced exchange prohibition. The OTC Markets Group provided the solution through its OTCQX tier, which requires audited financials and SEC reporting but operates outside the major exchanges. The first significant U.S. cannabis operator to trade publicly was MedMen Enterprises, which began trading on the Canadian Securities Exchange in May 2018 with U.S. OTC access. Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs followed in 2018-2019, creating the "Big Four" MSOs that dominated public cannabis markets. By December 2020, approximately 350 cannabis-related companies traded on OTC markets with combined market capitalization exceeding $45 billion. The sector attracted retail investors and specialized cannabis funds but remained largely inaccessible to institutional capital.

The Biden Administration and Rescheduling Initiation (2022-2024)

President Joe Biden issued a presidential directive on October 6, 2022, ordering the Department of Health and Human Services and the Department of Justice to review cannabis scheduling. HHS completed its review in August 2023, recommending rescheduling to Schedule III based on accepted medical use and lower abuse potential compared to Schedule I and II substances. The DEA published a Notice of Proposed Rulemaking in the Federal Register on May 21, 2024, formally proposing to reschedule cannabis to Schedule III under 21 C.F.R. § 1308. The proposal triggered a 60-day comment period that generated more than 43,000 public submissions—the most in DEA rulemaking history. An administrative law judge hearing occurred from September through November 2024, with testimony from medical researchers, state regulators, law enforcement, and industry representatives. The DEA published its final rule on January 15, 2025, rescheduling cannabis to Schedule III effective February 1, 2025. The rule maintained federal prohibition on non-medical use but reclassified cannabis alongside anabolic steroids and ketamine, acknowledging accepted medical applications.

Exchange Policy Evolution and the First Uplisting Announcements (2025-2026)

Nasdaq and the NYSE began internal policy reviews immediately following the January 2025 final rule. The exchanges faced complex questions about whether Schedule III status removed the federal illegality barrier, given that state-licensed operators still technically violated the Controlled Substances Act by operating without DEA registration. The DEA clarified the registration pathway in guidance published March 12, 2025. State-licensed operators could apply for DEA registration as Schedule III handlers, subject to facility inspection, security requirements, and ongoing compliance monitoring. Registration fees ranged from $3,500 to $18,000 depending on facility type and state location. Nasdaq announced updated listing standards on June 3, 2025, stating that cannabis companies with valid DEA registration and state licenses would be eligible for listing consideration subject to standard financial and governance requirements. The NYSE followed with similar guidance on June 17, 2025. Curaleaf Holdings became the first MSO to announce uplisting intentions on August 8, 2025, stating it had submitted DEA registration applications for all cultivation and processing facilities. Green Thumb Industries followed on August 22, 2025. By year-end 2025, seven MSOs had publicly announced uplisting preparations. The first successful uplisting occurred on March 4, 2026, when Curaleaf began trading on the Nasdaq under ticker symbol CURA after completing a 1-for-10 reverse stock split to meet the $4 minimum bid price requirement. Shares rose 34% in the first week of trading as institutional buyers entered positions.

The Ascend Wellness Announcement and Current Wave (July 2026)

Ascend Wellness Holdings announced on July 14, 2026, that it had received DEA registration approval for its facilities in Illinois, Massachusetts, Michigan, New Jersey, and Ohio. The company stated it would pursue a reverse stock split to meet Nasdaq minimum price requirements and expected to complete uplisting by fourth quarter 2026. As of mid-July 2026, four MSOs have completed uplisting to major exchanges, nine have announced active uplisting processes, and an additional 12 mid-sized operators have stated intentions to pursue uplisting by 2027. The wave represents the most significant structural change in cannabis capital markets since state legalization began.

Key Players in the Uplisting Process

Multi-State Operators Pursuing Uplisting

Curaleaf Holdings operates 154 dispensaries across 17 states and completed the first MSO uplisting to Nasdaq on March 4, 2026. The company reported $1.4 billion in revenue for fiscal year 2025 and maintains cultivation facilities in Florida, New Jersey, Pennsylvania, Arizona, and Massachusetts. Curaleaf's successful uplisting established the template for subsequent operators including reverse stock split mechanics and DEA registration sequencing. Green Thumb Industries operates 88 retail locations under the Rise and Essence brands across 15 states. The company completed Nasdaq uplisting on April 18, 2026, and reported immediate benefits including a $200 million institutional equity investment from Fidelity Investments within 30 days of listing. Green Thumb reported $1.1 billion in revenue for 2025. Trulieve Cannabis dominates the Florida market with 185 dispensaries statewide and operates in Pennsylvania, West Virginia, Maryland, and Arizona. The company announced NYSE uplisting plans in May 2026 and completed its reverse stock split on June 30, 2026. Trulieve reported $1.3 billion in revenue for 2025, with 68% derived from Florida operations. Verano Holdings operates 135 dispensaries across 13 states with significant presence in Illinois, Pennsylvania, and New Jersey. The company announced Nasdaq uplisting intentions in June 2026 and received DEA registration for all facilities by early July. Verano reported $950 million in revenue for 2025. Ascend Wellness Holdings operates 28 dispensaries in Illinois, Massachusetts, Michigan, New Jersey, and Ohio, focusing on high-margin limited-license markets. The company's July 14, 2026 announcement included confirmation of DEA registration and plans for a reverse stock split to meet Nasdaq requirements. Ascend reported $570 million in revenue for 2025.

Stock Exchanges and Regulatory Bodies

Nasdaq Stock Market established the first clear pathway for cannabis operator listing in June 2025 guidance. The exchange requires minimum $4 bid price, $50 million market capitalization, $10 million in stockholders' equity, and compliance with corporate governance standards including independent board majority and audit committee. Nasdaq charges $125,000-$295,000 in initial listing fees depending on shares outstanding, plus annual fees of $43,000-$155,000. New York Stock Exchange published similar eligibility standards in June 2025 with higher financial thresholds including $100 million market capitalization and $100 million in revenue for the most recent fiscal year. NYSE initial listing fees range from $150,000 to $500,000 with annual fees of $38,000-$500,000 based on shares outstanding. Drug Enforcement Administration processes registration applications for Schedule III cannabis handlers under authority granted by 21 U.S.C. § 823. The agency established a dedicated Cannabis Registration Unit in February 2025 that had processed more than 800 facility registrations by July 2026. DEA registration requires background checks on beneficial owners, facility security inspections, and ongoing compliance with record-keeping and reporting requirements under 21 C.F.R. § 1304. Securities and Exchange Commission maintains oversight of all exchange-listed companies through periodic reporting requirements including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports for material events. The SEC has not issued cannabis-specific guidance but applies standard disclosure requirements to uplisted operators including risk factor disclosure, management discussion and analysis, and executive compensation reporting.

Institutional Investors and Capital Providers

Major institutional investors began establishing cannabis positions immediately following the first successful uplistings in early 2026. Fidelity Investments disclosed a $200 million position in Green Thumb Industries in May 2026. Vanguard Group filed 13F disclosures showing positions in Curaleaf and Trulieve totaling $340 million as of June 30, 2026. State pension funds in New York, California, and Illinois have begun cannabis allocations following uplisting, with combined positions exceeding $150 million by mid-2026.

Legal and Regulatory Framework

MSO uplisting operates at the intersection of federal drug law, securities regulation, and exchange listing standards—a framework that shifted fundamentally with Schedule III rescheduling but maintains significant compliance complexity.

Controlled Substances Act and Schedule III Status

The Controlled Substances Act establishes five schedules of controlled substances under 21 U.S.C. § 812, with placement determined by abuse potential, accepted medical use, and safety profile. Cannabis rescheduling to Schedule III under the January 15, 2025 final rule placed it in the same category as anabolic steroids, ketamine, and certain codeine preparations. Schedule III status maintains federal prohibition on non-medical possession and distribution but permits registered handlers to engage in medical cannabis activities. Registration requires DEA approval under 21 U.S.C. § 823(f), which authorizes the Attorney General to register practitioners and manufacturers for Schedule III substances. The DEA considers factors including state licensure, facility security, record-keeping systems, and beneficial owner background checks. Critically, Schedule III rescheduling did not legalize adult-use cannabis or create a federal medical cannabis program. State-licensed operators remain in technical violation of federal law when serving adult-use customers, creating ongoing legal risk despite DEA registration for medical activities. This tension has not prevented exchange listing because the exchanges focus on the medical cannabis operations that occur under valid DEA registration.

Securities Law and Exchange Act Reporting

Companies listing on Nasdaq or the NYSE become subject to Securities Exchange Act of 1934 reporting requirements under 15 U.S.C. § 78m. This includes Form 10-K annual reports due within 60-90 days of fiscal year end, Form 10-Q quarterly reports due within 40-45 days of quarter end, and Form 8-K current reports for material events within four business days. Cannabis operators face enhanced disclosure obligations in several areas. Risk factors must address federal-state law conflicts, potential DEA enforcement actions, banking limitations under the Bank Secrecy Act, and 280E tax burdens under 26 U.S.C. § 280E that prohibit business expense deductions for Schedule I and II trafficking. Management discussion and analysis sections must quantify 280E impact on effective tax rates, which typically range from 45% to 75% for plant-touching operators. The SEC applies standard materiality thresholds to cannabis companies without sector-specific exemptions. This creates disclosure challenges around state-level regulatory violations, product recalls, and license suspensions that might be immaterial for other industries but carry heightened significance in cannabis due to limited license availability and regulatory scrutiny.

Exchange Listing Standards

Nasdaq maintains three listing tiers with varying requirements. The Nasdaq Global Select Market requires $550 million market capitalization, $10 million stockholders' equity, and $110 million aggregate market value of publicly held shares. The Nasdaq Global Market requires $75 million market capitalization and $5 million stockholders' equity. The Nasdaq Capital Market—the entry tier for most cannabis operators—requires $50 million market capitalization, $4 million stockholders' equity, and $4 minimum bid price. The minimum bid price requirement creates the primary barrier for cannabis operators whose shares trade below $4 due to years of OTC market volatility and dilution. Companies typically execute reverse stock splits to meet the threshold, consolidating shares at ratios between 1-for-5 and 1-for-15. Curaleaf implemented a 1-for-10 reverse split, reducing shares outstanding from 820 million to 82 million and increasing share price from $2.80 to $28. Corporate governance requirements apply uniformly to cannabis operators. Companies must maintain a majority-independent board of directors, establish audit committees composed entirely of independent directors, and adopt codes of business conduct. These requirements often necessitate board restructuring for MSOs that operated with founder-dominated boards during OTC trading.

State Licensing and Regulatory Approval

State cannabis regulators in markets including Illinois, Massachusetts, and New Jersey require notification and sometimes approval before licensees undergo significant corporate changes including exchange uplisting. The Illinois Department of Financial and Professional Regulation requires 30-day advance notice of any change in corporate structure or ownership exceeding 5%. Massachusetts Cannabis Control Commission regulations at 935 CMR 500.101 require prior approval for changes in beneficial ownership. These requirements create sequencing challenges for uplisting. Operators must coordinate DEA registration, exchange application, reverse stock split shareholder approval, and state regulatory notifications across multiple jurisdictions with varying timelines. Curaleaf's uplisting process took seven months from initial DEA application to Nasdaq trading, while Green Thumb completed the process in five months due to streamlined state approvals.

State-by-State Regulatory Landscape

State cannabis programs vary significantly in their treatment of publicly-traded operators and exchange listing, with some states facilitating uplisting and others imposing additional scrutiny on ownership changes.

Illinois

Illinois operates a limited-license adult-use program that issued 185 dispensary licenses and 21 cultivation licenses through lottery and social equity processes. The state requires operators to notify the Department of Financial and Professional Regulation within 30 days of any ownership change exceeding 5% under 410 ILCS 705/15-30. Exchange uplisting triggers this requirement due to increased shareholder liquidity and potential ownership turnover. Green Thumb Industries, Cresco Labs, and Verano Holdings all maintain significant Illinois operations and completed state notifications as part of their uplisting processes. The state approved all notifications without additional conditions, establishing Illinois as an uplisting-friendly jurisdiction. Illinois does not impose ownership caps on publicly-traded companies.

Massachusetts

Massachusetts Cannabis Control Commission regulations at 935 CMR 500.101 require prior approval for any change in beneficial ownership of a marijuana establishment. The Commission defines beneficial ownership as direct or indirect control exceeding 10% of voting securities. Exchange uplisting creates potential beneficial ownership changes as institutional investors acquire positions. Curaleaf and Ascend Wellness both operate in Massachusetts and submitted ownership change applications to the CCC as part of uplisting preparation. The Commission approved both applications after 45-60 day review periods, requiring operators to submit quarterly beneficial ownership reports identifying all shareholders exceeding 10% positions. This creates ongoing compliance obligations but has not prevented uplisting.

Florida

Florida operates a vertically-integrated license structure that limits the number of operators through a competitive application process. The state does not impose specific restrictions on publicly-traded companies or exchange listing. Trulieve Cannabis, the dominant Florida operator with 185 dispensaries statewide, faced no state regulatory barriers to NYSE uplisting beyond standard license maintenance requirements. Florida's regulatory approach focuses on operational compliance rather than ownership structure, making it one of the most favorable states for publicly-traded operators. The state does not require ownership change notifications for passive investors acquiring shares on public exchanges.

Pennsylvania

Pennsylvania medical cannabis regulations at 28 Pa. Code § 1141.32 require operators to notify the Department of Health within 30 days of any change in principals, financial backers, or operators. The state defines these terms broadly to include beneficial owners with 5% or greater ownership interests. Exchange uplisting creates notification obligations as institutional investors cross the 5% threshold. Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs all operate in Pennsylvania and completed state notifications during uplisting processes. The Department of Health approved all notifications without additional conditions, though review periods extended 60-90 days in some cases. Pennsylvania does not prohibit publicly-traded operators but maintains heightened scrutiny on ownership changes.

New Jersey

New Jersey Cannabis Regulatory Commission rules at N.J.A.C. 17:30-7.8 require prior approval for any change in ownership or control of a licensed cannabis business. The Commission interprets this requirement to include exchange uplisting due to the potential for significant shareholder turnover and institutional investment. Curaleaf, Ascend Wellness, and Verano Holdings submitted ownership change applications to the CRC during uplisting preparation. The Commission approved all applications after 45-60 day reviews, requiring operators to submit quarterly beneficial ownership reports and maintain New Jersey resident representation on boards of directors. These requirements create ongoing compliance obligations but have not prevented uplisting.

Market and Business Implications

Exchange uplisting fundamentally alters MSO capital structure, cost of capital, and competitive dynamics—changes that ripple through wholesale markets, M&A activity, and operator strategy.

Cost of Capital Reduction

Multi-state operators trading on OTC markets reported weighted average cost of capital between 12% and 18% in 2025, reflecting illiquidity premiums, institutional investor restrictions, and federal legal risk. Exchange uplisting reduces cost of capital through multiple mechanisms including improved liquidity, institutional investor access, and enhanced price discovery. Curaleaf reported cost of equity declining from 15% pre-uplisting to 10.5% within 90 days of Nasdaq listing, according to company investor presentations. Green Thumb Industries refinanced $300 million in 9.5% senior notes with 6.75% notes following uplisting, saving $8.25 million annually in interest expense. These capital cost reductions translate directly to improved return on invested capital and enhanced ability to fund expansion. The cost of capital differential creates competitive advantages for uplisted operators over OTC-traded competitors. Uplisted MSOs can underbid OTC operators for acquisition targets, invest more aggressively in facility automation and product innovation, and sustain longer periods of market-share-focused pricing in emerging markets. This dynamic accelerates industry consolidation as uplisted operators acquire smaller competitors.

Institutional Investment Flows

Institutional investors managing approximately $40 trillion in assets gained access to cannabis operators through exchange uplisting. Pension funds, mutual funds, and index funds face internal policies or fiduciary restrictions limiting OTC securities to small percentages of portfolios due to liquidity and regulatory concerns. Exchange listing removes these barriers. Fidelity Investments established a $200 million position in Green Thumb Industries within 30 days of Nasdaq uplisting. Vanguard Group disclosed combined positions exceeding $340 million in Curaleaf and Trulieve as of June 30, 2026. State pension funds in New York, California, and Illinois began cannabis allocations following uplisting, with combined positions exceeding $150 million by mid-2026. Index inclusion represents a significant future catalyst for institutional flows. The S&P 500 requires $14.6 billion market capitalization for inclusion as of 2026 criteria—a threshold no cannabis operator currently meets. The S&P MidCap 400 requires $3.7-14.6 billion market capitalization, placing Curaleaf, Green Thumb, and Trulieve within range for potential inclusion by 2027-2028. Index inclusion would trigger automatic purchases by index funds managing trillions in assets.

Merger and Acquisition Activity

Exchange uplisting enables stock-based acquisitions using liquid shares as currency—a capability that transforms M&A dynamics. OTC-traded operators face challenges using shares for acquisitions because target company shareholders demand liquidity and price certainty that OTC markets cannot provide. Exchange-listed shares trade with tight bid-ask spreads, high daily volume, and transparent pricing that facilitates stock-based deals. Curaleaf announced its first post-uplisting acquisition on May 15, 2026, agreeing to acquire Arizona-based operator Harvest Health & Recreation for $425 million in stock. The deal valued Harvest at 0.8x revenue using Curaleaf's Nasdaq-traded shares, compared to 1.2-1.5x revenue multiples typical for all-cash OTC market deals. The valuation differential reflects the liquidity premium of exchange-traded shares. Industry analysts project 15-25 significant M&A transactions in the 12 months following the first wave of uplistings, with uplisted operators as acquirers in 80% of deals. This consolidation wave will reduce the number of meaningful MSO competitors from approximately 25 in mid-2026 to 10-12 by 2028, according to projections from Viridian Capital Advisors.

Wholesale Market Impacts

Exchange uplisting affects wholesale cannabis markets through improved operator access to working capital and growth funding. Wholesale prices for cannabis flower declined 35-45% across major markets from 2022 to 2025 due to oversupply, limited retail expansion, and operator capital constraints that prevented market exit. Uplisted operators with improved capital access can sustain operations through price compression that forces undercapitalized competitors to exit. In Michigan, wholesale flower prices averaged $800-900 per pound in mid-2026, down from $1,400-1,600 in 2024. Uplisted operators including Green Thumb Industries expanded Michigan cultivation capacity by 40% in the six months following Nasdaq listing, betting that capital advantages would enable market share gains as competitors exited. This strategy accelerated price declines but positioned uplisted operators to capture share in a consolidating market. California wholesale markets showed similar dynamics. Curaleaf announced plans to double California cultivation capacity in July 2026, six months after Nasdaq uplisting, despite wholesale flower prices below $600 per pound. The expansion reflected confidence that capital advantages would enable survival through a multi-year consolidation period that eliminates 30-40% of current operators.

280E Tax Treatment and Profitability

Internal Revenue Code Section 280E prohibits business expense deductions for trafficking in Schedule I and II controlled substances under 26 U.S.C. § 280E. Cannabis rescheduling to Schedule III removed 280E application to cannabis operators, enabling full deduction of business expenses including rent, salaries, marketing, and professional fees. The 280E elimination reduces effective tax rates for cannabis operators from 45-75% to 21-28%, depending on state tax burdens. Curaleaf reported effective tax rate declining from 68% in 2024 to 26% in first quarter 2026 following Schedule III rescheduling. This tax reduction translated to $45 million in additional annual cash flow for Curaleaf, funding expansion and debt reduction. The 280E benefit accrues to all cannabis operators regardless of exchange listing, but uplisted operators gain additional advantages through improved access to tax planning strategies and capital for tax-efficient structuring. Exchange-listed companies attract sophisticated tax advisory firms and can execute complex strategies including international holding company structures and intellectual property licensing arrangements that optimize global tax burdens.

What Experts Say

Industry analysts, securities lawyers, and operator executives describe exchange uplisting as the most significant structural change in cannabis capital markets since state legalization began, while noting execution risks and ongoing federal-state legal tensions. Emily Paxhia, co-founder of Poseidon Investment Management, said in a June 2026 interview with Bloomberg that institutional capital inflows to cannabis operators could reach $5-8 billion in the 24 months following the first wave of uplistings. According to Paxhia, pension funds and mutual funds have been waiting for exchange listing to establish cannabis positions, and the removal of OTC trading barriers will accelerate institutional adoption. Andrew Kline, partner at Perkins Coie and former senior counsel at the National Cannabis Industry Association, stated in congressional testimony on May 8, 2026, that exchange uplisting does not eliminate federal legal risk for cannabis operators. According to Kline, state-licensed operators serving adult-use customers remain in technical violation of the Controlled Substances Act despite DEA registration for medical activities, creating potential enforcement risk if federal policy shifts. Boris Jordan, executive chairman of Curaleaf Holdings, said in the company's first quarter 2026 earnings call that Nasdaq uplisting reduced Curaleaf's cost of equity by approximately 450 basis points within 90 days of listing. According to Jordan, institutional investors including Fidelity, Vanguard, and State Street established positions totaling more than $400 million in Curaleaf shares during the first quarter of exchange trading, validating the strategic rationale for uplisting despite the costs and complexity of the process. Ben Kovler, chief executive officer of Green Thumb Industries, stated in an April 2026 investor presentation that exchange listing enables stock-based acquisitions that were impractical when trading OTC. According to Kovler, Green Thumb plans to pursue 3-5 acquisitions annually using stock as primary consideration, leveraging the liquidity and price transparency of Nasdaq-traded shares to offer attractive terms to target company shareholders. Vivien Azer, managing director and senior research analyst at Cowen, wrote in a July 2026 research note that exchange uplisting creates a two-tier cannabis industry with uplisted operators enjoying 300-500 basis point cost of capital advantages over OTC competitors. According to Azer, this differential will drive industry consolidation as uplisted operators acquire OTC-traded competitors at discounted valuations, reducing the number of meaningful MSO competitors from 25 to 10-12 by 2028.

What's Next: Timeline and Decision Points

The next 18 months will determine whether exchange uplisting becomes the industry standard or remains limited to the largest MSOs, with key decision points including additional operator uplistings, institutional investment velocity, and potential federal legislative changes.

Near-Term Operator Uplistings (Q3-Q4 2026)

Nine multi-state operators have announced active uplisting processes as of mid-July 2026, with expected completion dates ranging from August 2026 through first quarter 2027. Ascend Wellness Holdings targets fourth quarter 2026 completion following its July 14 announcement. Verano Holdings expects Nasdaq listing in September 2026. Cresco Labs announced October 2026 target date for NYSE listing. Mid-sized operators including Columbia Care, Ayr Wellness, and Jushi Holdings face higher barriers to uplisting due to market capitalizations below $200 million and limited liquidity in current OTC trading. These operators may pursue mergers with uplisted MSOs rather than independent uplisting, accelerating industry consolidation.

Index Inclusion Considerations (2027-2028)

S&P Dow Jones Indices maintains market capitalization and liquidity requirements for index inclusion that currently exclude all cannabis operators. The S&P MidCap 400 requires $3.7-14.6 billion market capitalization and $250 million average daily trading value over the prior six months. Curaleaf's $4.2 billion market capitalization and Green Thumb's $3.9 billion market capitalization as of July 2026 place both companies within range for potential MidCap 400 inclusion by late 2027. Index inclusion would trigger automatic purchases by index funds and ETFs tracking the S&P MidCap 400, potentially adding $500 million to $1 billion in institutional demand for each included operator. This represents a significant catalyst for share price appreciation and further cost of capital reduction.

Federal Legislative Developments

The SAFER Banking Act, which would provide explicit safe harbor for financial institutions serving state-licensed cannabis businesses, passed the Senate in March 2026 but remains pending in the House of Representatives as of July 2026. The legislation does not directly affect exchange listing but would reduce banking barriers that create operational challenges for uplisted operators. Comprehensive cannabis legalization legislation including the Cannabis Administration and Opportunity Act remains under committee consideration in both chambers. Passage would eliminate federal-state legal conflicts and remove remaining barriers to institutional investment, but political dynamics suggest enactment is unlikely before 2028.

International Operator Activity

Canadian licensed producers including Canopy Growth, Tilray Brands, and Cronos Group have traded on major U.S. exchanges since 2018 based on Canadian operations. These operators are evaluating acquisitions of U.S. MSOs now that exchange listing removes a key competitive disadvantage. Tilray CEO Irwin Simon stated in a June 2026 earnings call that the company is evaluating 3-5 U.S. acquisition targets with enterprise values between $500 million and $2 billion. Cross-border M&A between Canadian LPs and U.S. MSOs could accelerate industry consolidation and create the first multi-billion-dollar global cannabis operators with operations across North America and international medical markets.

Further Reading and Primary Sources

• Drug Enforcement Administration, "Schedules of Controlled Substances: Rescheduling of Marijuana," Final Rule, Federal Register Vol. 90, No. 10 (January 15, 2025), available at https://www.federalregister.gov
• Nasdaq Stock Market, "Initial Listing Guide," updated June 2025, available at https://listingcenter.nasdaq.com/assets/initialguide.pdf
• New York Stock Exchange, "Listed Company Manual," Section 102.01 (Minimum Numerical Standards), available at https://nyseguide.srorules.com
• Securities and Exchange Commission, "Form 10-K Annual Report Requirements," 17 C.F.R. § 249.310, available at https://www.sec.gov
• Viridian Capital Advisors, "Cannabis Deal Tracker," Q